Abeona Therapeutics faces securities fraud probe after Q2 revenue recognition issues.

Pomerantz LLP is investigating Abeona Therapeutics for potential securities fraud following the company's Q2 2026 report. Abeona disclosed that only four out of five treatments for its therapy ZEVASKYN were recognized for revenue due to batch issues, causing a nearly 15% stock price drop. The investigation will determine if Abeona or its executives engaged in unlawful practices. Investors affected may join a class action lawsuit as the case develops.